GLP-1 (Glucagon-like Peptide-1) is a natural incretin hormone that: Stimulates insulin secretion (when glucose is high) Suppresses glucagon release Slows gastric emptying Increases satiety reducing food intake Why GLP-1 Therapy Stands Out Glycemic Control Lowers HbA1c by ~11.5% with minimal hypoglycemia risk Weight Loss 515 kg depending on drug/dose (semaglutide leads the way) Cardiovascular Protection Reduced major CV events (MACE) in trials like LEADER, SUSTAIN, REWIND Renal Protection Slows progression of diabetic kidney disease Convenience Available as daily or weekly injections and even oral semaglutide Key Clinical Trials LEADER (Liraglutide) CV mortality & MACE SUSTAIN-6 (Semaglutide) CV events & strong weight loss REWIND (Dulaglutide) CV protection even in lower-risk populations STEP Trials (Semaglutide) Double-digit weight reduction in obesity The Bigger Picture GLP-1 therapy goes beyond insulin and beyond diabetes
A Longevity Pro Panel that includes fasting insulin, HbA1c, and inflammatory markers provides the biomarker foundation to assess whether a MOTS-c protocol is producing measurable metabolic improvements over a 12-week cycle
So to replenish and make up for the loss, it can be supplemented in our diet, in the form of a capsule
At our Atlanta clinic, we offer two primary GLP-1 options: Semaglutide: A once-weekly injection that targets GLP-1 receptors to reduce appetite and improve blood sugar control
don't work against it Satiating but not heavy protein hit without feeling overfull on a suppressed stomach The Weight Loss Math A 180-pound person on Wegovy or Ozempic needs 126180g protein daily
